Login to Your Account



ACC Roundup


Tuesday, March 27, 2012
• AstraZeneca plc, of London, said results from a subanalysis of the PLATO genetic substudy were consistent with the overall outcome of the study, comparing Brilinta (ticagrelor) to Plavix (clopidogrel, Sanofi SA and Bristol-Myers Squibb Co.), even after poor clopidogrel metabolizers were excluded.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription